Patents by Inventor Roman SHIMANOVICH

Roman SHIMANOVICH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID STATE FORMS
    Publication number: 20240067647
    Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Application
    Filed: October 23, 2023
    Publication date: February 29, 2024
    Applicant: AMGEN INC.
    Inventors: Mary CHAVES, Patricia LOPEZ, Prashant AGARWAL, Albert AMEGADZIE, Stephanie AZALI, Roman SHIMANOVICH, Ron C. KELLY, Darren Leonard REID
  • Solid state forms
    Patent number: 11827635
    Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: November 28, 2023
    Assignee: Amgen Inc.
    Inventors: Mary Chaves, Patricia Lopez, Prashant Agarwal, Albert Amegadzie, Stephanie Azali, Roman Shimanovich, Ron C. Kelly, Darren Leonard Reid
  • SOLID STATE FORMS
    Publication number: 20220235045
    Abstract: The present invention provides a crystalline form and stable salts of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1- piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several hydrochloride salt forms, phosphate salt form, mesylate salt form, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Application
    Filed: May 20, 2020
    Publication date: July 28, 2022
    Inventors: Mary CHAVES, Ron C. KELLY, Prashant AGARWAL, Stephan D. PARENT, Darren Leonard REID, Roman SHIMANOVICH
  • SOLID STATE FORMS
    Publication number: 20220106313
    Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: AMGEN INC.
    Inventors: Mary CHAVES, Patricia LOPEZ, Prashant AGARWAL, Albert AMEGADZIE, Stephanie AZALI, Roman SHIMANOVICH, Ron C. KELLY, Darren Leonard REID
  • Solid state forms
    Patent number: 11236091
    Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: February 1, 2022
    Assignee: Amgen Inc.
    Inventors: Mary Chaves, Patricia Lopez, Prashant Agarwal, Albert Amegadzie, Stephanie Azali, Roman Shimanovich, Ron C. Kelly, Darren Leonard Reid
  • SOLID STATE FORMS
    Publication number: 20200369662
    Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Application
    Filed: May 20, 2020
    Publication date: November 26, 2020
    Applicant: AMGEN INC.
    Inventors: Mary CHAVES, Patricia LOPEZ, Prashant AGARWAL, Albert AMEGADZIE, Stephanie AZALI, Roman SHIMANOVICH, Ron C. KELLY, Darren Leonard REID
  • Polymorphic forms and co-crystals of a c-Met inhibitor
    Patent number: 10344041
    Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: July 9, 2019
    Assignee: Amgen, Inc.
    Inventors: David Bauer, Matthew Bio, Melanie Cooke, Katrina W. Copeland, Matthew Peterson, Michele Potashman, Roman Shimanovich, Helming Tan
  • POLYMORPHIC FORMS AND CO-CRYSTALS OF A C-MET INHIBITOR
    Publication number: 20180244696
    Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.
    Type: Application
    Filed: April 30, 2018
    Publication date: August 30, 2018
    Inventors: David BAUER, Matthew BIO, Melanie COOKE, Katrina W. COPELAND, Matthew PETERSON, Michele POTASHMAN, Roman SHIMANOVICH, Helming TAN
  • Polymorphic forms and co-crystals of a c-Met inhibitor
    Patent number: 9981988
    Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 29, 2018
    Assignee: AMGEN INC.
    Inventors: David Bauer, Matthew Bio, Melanie Cooke, Katrina W. Copeland, Matthew Peterson, Michele Potashman, Roman Shimanovich, Helming Tan
  • POLYMORPHIC FORMS AND CO-CRYSTALS OF A C-MET INHIBITOR
    Publication number: 20170029443
    Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.
    Type: Application
    Filed: October 14, 2016
    Publication date: February 2, 2017
    Inventors: David BAUER, Matthew BIO, Melanie COOKE, Katrina W. COPELAND, Matthew PETERSON, Michele POTASHMAN, Roman SHIMANOVICH, Helming TAN